Novo Nordisk CagriSema -2.6%: Pipeline Shock and Price War
Novo Nordisk CagriSema flops in Phase 3, stock -2.6%: What does the study shock and price war for Wegovy and Ozempic mean?
Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.
Nestlé Reorganization: 16,000 Jobs Cut Amid Cost-Cutting Shock
Nestlé's reorganization involves 16,000 job cuts, a billion-savings plan, and portfolio sales—what does this mean for investors?